COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5microg...

ID
40872011000001104
Virtual product
Generic COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials
Name
COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials
Abbreviated name
COVID-19 Vacc VidPrevtyn (B.1.351) 0.5ml inj multidose vials
Description
COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi)
Date of name applicability
10 Jan 2023
Previous Name
COVID-19 Vaccine Sanofi (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose emulsion for injection multidose vials
Supplier
Sanofi
Licensed as
Medicines - MHRA/EMA
Previously licensed as
None
License change reason
Licence Granted
Date of change of licensing authority
10 Jan 2023
EMA (European Medicines Agency) Monitoring
1
Restrictions on availability
Restricted Availability
Licensed route
Intramuscular